70 195

Cited 0 times in

Effectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation

DC Field Value Language
dc.contributor.author김대훈-
dc.contributor.author김종윤-
dc.contributor.author김태훈-
dc.contributor.author박희남-
dc.contributor.author엄재선-
dc.contributor.author유희태-
dc.contributor.author이문형-
dc.contributor.author정보영-
dc.date.accessioned2022-08-23T00:25:16Z-
dc.date.available2022-08-23T00:25:16Z-
dc.date.issued2022-06-
dc.identifier.issn0039-2499-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/189421-
dc.description.abstractBackground: Frail patients with atrial fibrillation (AF) are less likely to receive anticoagulation than nonfrail patients with AF despite frailty being associated with poorer clinical outcomes including stroke. Using a population-based cohort, we sought to assess the effectiveness and safety of oral anticoagulants (OACs) in frail patients with AF. Methods: This retrospective cohort study analyzed 83 635 patients aged at least 65 years with AF and frailty (≥5 Hospital Frailty Risk Score) between January 1, 2013 and December 31, 2016 from the Korean National Health Insurance Service database. To account for the differences between patients receiving OAC or not and across different OAC regimens, propensity score-weighting was used. Net adverse clinical event, defined as the first event of ischemic stroke, major bleeding, or cardiovascular death, was compared. In addition, each individual outcome was examined separately. Results: In the study population (57.1% women; mean age, 78.5±7.2 years), a total of 14 968 net adverse clinical event, 3718 ischemic stroke, 5536 major bleeding, and 6188 cardiovascular death occurred. In comparison with no OAC use, OAC use was associated with lower risks of net adverse clinical event (hazard ratio, 0.78 [95% CI, 0.75-0.82]), ischemic stroke (hazard ratio, 0.91 [95% CI, 0.86-0.97]), and cardiovascular death (hazard ratio, 0.52 [95% CI, 0.49-0.55]), but no difference was observed for major bleeding (hazard ratio, 1.02 [95% CI, 0.95-1.10]). Compared with warfarin, all four individual direct OAC were associated with decreased risks of net adverse clinical event, ischemic stroke, major bleeding, and cardiovascular death. The associations for OAC use (compared to no OAC use) or direct OAC use (compared to warfarin) with favorable outcomes were more prominent in individuals with a higher CHA2DS2-VASc score of at least 3. Conclusions: Among frail patients with AF, OAC treatment was associated with a positive net clinical outcome. Direct OACs provided lower incidences of stroke, bleeding, and mortality, compared with warfarin.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherLippincott Williams & Wilkins-
dc.relation.isPartOfSTROKE-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.subject.MESHAdministration, Oral-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 and over-
dc.subject.MESHAnticoagulants / adverse effects-
dc.subject.MESHAtrial Fibrillation* / complications-
dc.subject.MESHAtrial Fibrillation* / drug therapy-
dc.subject.MESHAtrial Fibrillation* / epidemiology-
dc.subject.MESHFemale-
dc.subject.MESHFrail Elderly-
dc.subject.MESHFrailty* / chemically induced-
dc.subject.MESHFrailty* / complications-
dc.subject.MESHFrailty* / drug therapy-
dc.subject.MESHHemorrhage / chemically induced-
dc.subject.MESHHemorrhage / complications-
dc.subject.MESHHemorrhage / epidemiology-
dc.subject.MESHHumans-
dc.subject.MESHIschemic Stroke*-
dc.subject.MESHMale-
dc.subject.MESHRetrospective Studies-
dc.subject.MESHRisk Assessment-
dc.subject.MESHRisk Factors-
dc.subject.MESHStroke* / drug therapy-
dc.subject.MESHWarfarin / adverse effects-
dc.titleEffectiveness and Safety of Anticoagulation Therapy in Frail Patients With Atrial Fibrillation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학교실)-
dc.contributor.googleauthorDaehoon Kim-
dc.contributor.googleauthorPil-Sung Yang-
dc.contributor.googleauthorJung-Hoon Sung-
dc.contributor.googleauthorEunsun Jang-
dc.contributor.googleauthorHee Tae Yu-
dc.contributor.googleauthorTae-Hoon Kim-
dc.contributor.googleauthorJae-Sun Uhm-
dc.contributor.googleauthorJong-Youn Kim-
dc.contributor.googleauthorHui-Nam Pak-
dc.contributor.googleauthorMoon-Hyoung Lee-
dc.contributor.googleauthorGregory Y H Lip-
dc.contributor.googleauthorBoyoung Joung-
dc.identifier.doi10.1161/STROKEAHA.121.036757-
dc.contributor.localIdA00373-
dc.contributor.localIdA00926-
dc.contributor.localIdA01085-
dc.contributor.localIdA01776-
dc.contributor.localIdA02337-
dc.contributor.localIdA02535-
dc.contributor.localIdA02766-
dc.contributor.localIdA03609-
dc.relation.journalcodeJ02690-
dc.identifier.eissn1524-4628-
dc.identifier.pmid35109686-
dc.subject.keywordEditorials-
dc.subject.keywordanticoagulant-
dc.subject.keywordatrial fibrillation-
dc.subject.keywordfrailty-
dc.subject.keywordischemic stroke-
dc.subject.keywordmortality-
dc.contributor.alternativeNameKim, Dae Hoon-
dc.contributor.affiliatedAuthor김대훈-
dc.contributor.affiliatedAuthor김종윤-
dc.contributor.affiliatedAuthor김태훈-
dc.contributor.affiliatedAuthor박희남-
dc.contributor.affiliatedAuthor엄재선-
dc.contributor.affiliatedAuthor유희태-
dc.contributor.affiliatedAuthor이문형-
dc.contributor.affiliatedAuthor정보영-
dc.citation.volume53-
dc.citation.number6-
dc.citation.startPage1873-
dc.citation.endPage1882-
dc.identifier.bibliographicCitationSTROKE, Vol.53(6) : 1873-1882, 2022-06-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.